Screening study for women with a BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM mutation
Study Contact Information:
Ryan Buehler (lead coordinator), [email protected], 617-582-8833
The goal of MiDe is to develop a clinical diagnostic test to detect early onset ovarian cancer, as currently, there are no good screening or early detection tests available. The study is enrolling people with an inherited mutation with a gene linked to ovarian cancer, such as BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM. Participants can be expected to provide up to 4 tubes of blood every 6 months for up to 5 years. We can collect these samples through mobile phlebotomy all around the US. For more information, visit MiDeStudy.org.
Participating in the MiDe Study means that you’ll:
Note: Participants do not receive the results of their test.
Dipanjan Chowdhury, PhD: Dana-Farber Cancer Institute
Chief of the Division of Radiation and Genomic Stability in the Department of Radiation Oncology at Dana-Farber and a Professor of Medicine at Harvard Medical School
Kevin Elias, MD: Dana Farber Cancer Institute, Brigham and Women’s Hospital
Director of the Gynecologic Oncology Laboratory at Brigham and Women's Hospital, Assistant Professor at Harvard Medical School, and a visiting faculty member at the Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology
Judy E. Garber, MD, MPH: Dana-Farber Cancer Institute
Chief of the Division for Cancer Genetics and Prevention at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School. She also consults with the Pediatric Cancer Genetic Risk Program at Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Adults over the age of 18 with at least one ovary intact and no personal history of ovarian cancer are invited to join the MiDe Study. Additionally, eligible adults may:
If you are unsure if you may be eligible, please contact the study team.
Anyone under the age of 18 will not be considered for this trial. Adults over the age of 18 with no ovaries intact or have a personal history of ovarian cancer are also ineligible.
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.